| Date Filed | Type | Description |
| 08/14/2023 |
D
| Form D - Notice of Exempt Offering of Securities: |
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 08/10/2023 |
8-K
| Quarterly results |
| 08/04/2023 |
SC 13D
| Monograph Capital Holdings Advisors, LLC reports a 5.4% stake in UROGEN PHARMA LTD. |
| 08/01/2023 |
ARS
| Form ARS - Annual Report to Security Holders: |
| 08/01/2023 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 08/01/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 07/27/2023 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Regulation FD Disclosure, Other Events, ...|
Docs:
|
"UNITED STATES SECURITIES AND EXCHANGE COMMISSION",
"Form of July 2023 Pre-Funded Warrant",
"Securities Purchase Agreement, by and among UroGen Pharma Ltd. and the Purchasers named therein",
"UroGen Announces $120 Million Private Placement of Ordinary Shares PRINCETON, N.J.—July 27, 2023— UroGen Pharma Ltd. , a biotech company dedicated to developing and commercializing innovative solutions that treat urothelial and specialty cancers, today announced that it has entered into a definitive securities purchase agreement in connection with a private placement to selected institutional and accredited investors. RA Capital Management L.P. and Great Point Partners LLC led the Private Placement, which also included Acorn Bioventures, Monograph Capital and Horton Capital Partners Fund, LP. UroGen expects to receive gross proceeds of approximately $120 million, before deducting placement agent commissions and other offering expenses. UroGen intends to use the net proceeds of the Private ...",
"Company Presentation",
"Trial Results Slides" |
|
| 07/25/2023 |
8-K
| Quarterly results |
| 06/12/2023 |
SC 13G/A
| MENORA MIVTACHIM HOLDINGS LTD. reports a 12.4% stake in UroGen Pharma Ltd. |
| 05/11/2023 |
8-K
| Quarterly results |
| 05/11/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/01/2023 |
10-K/A
| Annual Report for the period ended December 31, 2022 [amend] |
| 03/24/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
| 03/22/2023 |
8-K
| Quarterly results |
| 02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
| 12/02/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 12/01/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
| 11/30/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 11/16/2022 |
S-3/A
| Form S-3/A - Registration statement under Securities Act of 1933: [Amend] |
| 11/15/2022 |
S-3
| Form S-3 - Registration statement under Securities Act of 1933: |
| 11/10/2022 |
8-K
| Quarterly results |
| 11/10/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
| 11/09/2022 |
8-K
| Quarterly results |
| 10/21/2022 |
8-K
| Quarterly results |
| 09/12/2022 |
8-K
| Appointed a new director |
| 08/11/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
| 08/11/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
| 08/11/2022 |
8-K
| Quarterly results |
| 07/08/2022 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
| 06/13/2022 |
8-K
| Quarterly results |
| 05/17/2022 |
DEFA14A
| Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material: |
| 05/10/2022 |
8-K
| Quarterly results |
| 05/10/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
|